Factors Associated With Failure to Publish Large Randomized Trials Presented at an Oncology Meeting
Krzyzanowska, Monika K.
Tannock, Ian F.
JAMA: The Journal of the American Medical Association 2003 July 23-30; 290(4): 495-501
CONTEXT: Large clinical trials are the criterion standard for making treatment decisions, and nonpublication of the results of such trials can lead to bias in the literature and contribute to inappropriate medical decisions. OBJECTIVES: To determine the rate of full publication of large randomized trials presented at annual meetings of the American Society of Clinical Oncology (ASCO), quantify bias against publishing nonsignificant results, and identify factors associated with time to publication. DESIGN: Survey of 510 abstracts from large (sample size, > or =200), phase 3, randomized controlled trials presented at ASCO meetings between 1989 and 1998. Trial results were classified as significant (P
Showing items related by title, author, creator and subject.
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology Aaronson, Neil K.; Ahmedzai, Sam; Bergman, Bengt; Bullinger, Monika (1993-03-03)
Relationships Between Authorship Contributions and Authors' Industry Financial Ties Among Oncology Clinical Trials Rose, Susannah L.; Krzyzanowska, Monika K.; Joffe, Steven (2010-03-10)PURPOSE To test the hypothesis that authors who play key scientific roles in oncology clinical trials, and who therefore have increased influence over the design, analysis, interpretation or reporting of trials, are more ...